KOD

SEC source: 0001209191-21-045036 · doc4.xml · derivative · entry 1

Dahiyat Bassil I · CIK 0001591312 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,368

Underlying: Common Stock · 7,368 shares

Expires 2031-06-29

F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2022 or one (1) day prior to Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.

SEC source: 0001638599-21-000594 · doc4_7287.xml · nonDerivative · entry 10

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,838,908

F13 · price: The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $90.01 to $91.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F4 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-21-000594 · doc4_7287.xml · nonDerivative · entry 9

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,808,687

F12 · price: The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $90.27 to $90.48, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F4 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-21-000594 · doc4_7287.xml · nonDerivative · entry 8

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,807,487

F11 · price: The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $89.98 to $90.97, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F4 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-21-000594 · doc4_7287.xml · nonDerivative · entry 7

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,795,756

F10 · price: The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $89.89 to $89.96, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F4 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-21-000594 · doc4_7287.xml · nonDerivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,791,909

F9 · price: The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $89.36 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F4 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-21-000594 · doc4_7287.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,784,830

F8 · price: The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $91.79 to $92.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F4 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-21-000594 · doc4_7287.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,774,371

F7 · price: The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $91.51 to $92.48, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F4 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-21-000594 · doc4_7287.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,751,926

F6 · price: The price reported in Column 4 is a weighted average price. These shares were traded by Life Sciences in multiple transactions at prices ranging from $90.49 to $91.48, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F4 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-21-000594 · doc4_7287.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,741,756

F2 · price: The price reported in Column 4 is a weighted average price. These shares were traded by Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $90.27 to $90.30, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F3 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F4 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001209191-21-042800 · doc4.xml · nonDerivative · entry 5

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,183

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $85.895 to $86.16, inclusive.

SEC source: 0001209191-21-042800 · doc4.xml · nonDerivative · entry 4

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,028

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $84.85 to $85.77, inclusive.

SEC source: 0001209191-21-042800 · doc4.xml · nonDerivative · entry 3

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,387

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $83.82 to $84.765, inclusive.

SEC source: 0001209191-21-042800 · doc4.xml · nonDerivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,271

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $82.735 to $83.66, inclusive.

SEC source: 0001209191-21-042800 · doc4.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,658

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $81.615 to $82.605, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.

SEC source: 0001209191-21-040741 · doc4.xml · nonDerivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,968

F3 · kind: The sale was made to cover tax withholding obligations in connection with vesting and settlement of 1/4th of the Reporting Person's performance-based RSU granted on December 30, 2019.

SEC source: 0001209191-21-040739 · doc4.xml · nonDerivative · entry 2

BORGESON JOHN A. · CIK 0001754045 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,990

F3 · kind: The sale was made to cover tax withholding obligations in connection with vesting and settlement of 1/4th of the Reporting Person's performance-based RSU granted on December 30, 2019.

SEC source: 0001209191-21-041809 · doc4.xml · derivative · entry 3

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,857

Underlying: Common Stock · 3,619 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

F3 · derivative.exercise_date: One-fourth (1/4th) of the RSU vest on each of the first four anniversaries of June 15, 2020, subject to Reporting Person's continued service on the applicable vesting date.

F3 · derivative.expiration_date: One-fourth (1/4th) of the RSU vest on each of the first four anniversaries of June 15, 2020, subject to Reporting Person's continued service on the applicable vesting date.

SEC source: 0001209191-21-041809 · doc4.xml · nonDerivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,133

F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

SEC source: 0001209191-21-041809 · doc4.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,587

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

SEC source: 0001209191-21-041807 · doc4.xml · derivative · entry 3

BORGESON JOHN A. · CIK 0001754045 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,857

Underlying: Common Stock · 3,619 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

F3 · derivative.exercise_date: One-fourth (1/4th) of the RSU vest on each of the first four anniversaries of June 15, 2020, subject to Reporting Person's continued service on the applicable vesting date.

F3 · derivative.expiration_date: One-fourth (1/4th) of the RSU vest on each of the first four anniversaries of June 15, 2020, subject to Reporting Person's continued service on the applicable vesting date.

SEC source: 0001209191-21-041807 · doc4.xml · nonDerivative · entry 2

BORGESON JOHN A. · CIK 0001754045 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,319

F2 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

SEC source: 0001209191-21-041807 · doc4.xml · nonDerivative · entry 1

BORGESON JOHN A. · CIK 0001754045 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,609

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

SEC source: 0001209191-21-040736 · doc4.xml · derivative · entry 1

PERLROTH VICTOR · CIK 0001754181 · Director · Chairman and CEO · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,850

Underlying: Common Stock · 111,850 shares

Expires 2029-12-29

F1 · derivative.exercise_date: On December 30, 2019 the Reporting Person was awarded a performance-based option. 1/4th of the shares subject to the option vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the shares subject to the option will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

SEC source: 0001209191-21-040741 · doc4.xml · derivative · entry 5

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,700

Underlying: Common Stock · 2,900 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

F4 · derivative.exercise_date: On December 30, 2019 the Reporting Person was awarded a performance-based award. 1/4th of the award vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the award will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

F4 · derivative.expiration_date: On December 30, 2019 the Reporting Person was awarded a performance-based award. 1/4th of the award vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the award will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

SEC source: 0001209191-21-040741 · doc4.xml · derivative · entry 4

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,600

Underlying: Common Stock · 11,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

F4 · derivative.exercise_date: On December 30, 2019 the Reporting Person was awarded a performance-based award. 1/4th of the award vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the award will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

F4 · derivative.expiration_date: On December 30, 2019 the Reporting Person was awarded a performance-based award. 1/4th of the award vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the award will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

SEC source: 0001209191-21-040741 · doc4.xml · derivative · entry 3

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,450

Underlying: Common Stock · 18,450 shares

Expires 2029-12-29

F4 · derivative.exercise_date: On December 30, 2019 the Reporting Person was awarded a performance-based award. 1/4th of the award vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the award will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

SEC source: 0001209191-21-040741 · doc4.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,115

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

F2 · balance_after: Includes 54 shares acquired under the 2018 Employee Stock Purchase Plan on May 31, 2021.

SEC source: 0001209191-21-040739 · doc4.xml · derivative · entry 5

BORGESON JOHN A. · CIK 0001754045 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,075

Underlying: Common Stock · 3,025 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

F4 · derivative.exercise_date: On December 30, 2019 the Reporting Person was awarded a performance-based award. 1/4th of the award vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the award will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

F4 · derivative.expiration_date: On December 30, 2019 the Reporting Person was awarded a performance-based award. 1/4th of the award vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the award will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

SEC source: 0001209191-21-040739 · doc4.xml · derivative · entry 4

BORGESON JOHN A. · CIK 0001754045 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,100

Underlying: Common Stock · 12,100 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

F4 · derivative.exercise_date: On December 30, 2019 the Reporting Person was awarded a performance-based award. 1/4th of the award vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the award will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

F4 · derivative.expiration_date: On December 30, 2019 the Reporting Person was awarded a performance-based award. 1/4th of the award vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the award will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

SEC source: 0001209191-21-040739 · doc4.xml · derivative · entry 3

BORGESON JOHN A. · CIK 0001754045 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,250

Underlying: Common Stock · 19,250 shares

Expires 2029-12-29

F4 · derivative.exercise_date: On December 30, 2019 the Reporting Person was awarded a performance-based award. 1/4th of the award vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the award will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.

SEC source: 0001209191-21-040739 · doc4.xml · nonDerivative · entry 1

BORGESON JOHN A. · CIK 0001754045 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.

F2 · balance_after: Includes 103 shares acquired under the 2018 Employee Stock Purchase Plan on May 31, 2021.

SEC source: 0001209191-21-035389 · doc4.xml · nonDerivative · entry 3

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,161

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $82.45 to $82.80, inclusive.

SEC source: 0001209191-21-035389 · doc4.xml · nonDerivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,558

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $81.365 to $82.36, inclusive.

SEC source: 0001209191-21-035389 · doc4.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,048

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $80.36 to $81.34, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.

SEC source: 0001209191-21-032823 · doc4.xml · derivative · entry 4

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,793

Underlying: Common Stock · 1,889 shares

Expires 2028-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: One-sixtieth of the shares subject to the option vested on November 3, 2018, and 1/60th of the shares subject to the option vest on the same day of each month thereafter.

SEC source: 0001209191-21-032823 · doc4.xml · derivative · entry 3

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 258,546

Underlying: Common Stock · 5,379 shares

Expires 2028-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vested on September 1, 2019, and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

SEC source: 0001209191-21-032823 · doc4.xml · nonDerivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,111

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-032823 · doc4.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,222

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-027961 · doc4.xml · derivative · entry 8

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,925

Underlying: Common Stock · 6,950 shares

Expires 2028-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vested on September 1, 2019 and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

SEC source: 0001209191-21-027961 · doc4.xml · nonDerivative · entry 7

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,843

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $114.68 to $115.33, inclusive.

SEC source: 0001209191-21-027961 · doc4.xml · nonDerivative · entry 6

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,025

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $113.365 to $114.06, inclusive.

SEC source: 0001209191-21-027961 · doc4.xml · nonDerivative · entry 5

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,620

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $111.88 to $112.58, inclusive.

SEC source: 0001209191-21-027961 · doc4.xml · nonDerivative · entry 4

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,289

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $110.87 to $111.845, inclusive.

SEC source: 0001209191-21-027961 · doc4.xml · nonDerivative · entry 3

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,939

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F3 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $109.845 to $110.84, inclusive.

SEC source: 0001209191-21-027961 · doc4.xml · nonDerivative · entry 2

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,560

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $108.82 to $109.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.

SEC source: 0001209191-21-027961 · doc4.xml · nonDerivative · entry 1

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-022881 · doc4.xml · derivative · entry 6

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,875

Underlying: Common Stock · 6,950 shares

Expires 2028-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vested on September 1, 2019 and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

SEC source: 0001209191-21-022881 · doc4.xml · nonDerivative · entry 5

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,843

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $133.37 to $133.46, inclusive.

SEC source: 0001209191-21-022881 · doc4.xml · nonDerivative · entry 4

EHRLICH JASON · CIK 0001754049 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,049

F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $132.165 to $132.71, inclusive.